Bausch Health Discusses Strategic Options for Bausch + Lomb
During its third-quarter 2026 earnings call, Bausch Health Companies Inc. addressed potential strategic options regarding its ownership stake in Bausch + Lomb Corporation.
Stocks · News reference
Bausch + Lomb Corporation announced its third-quarter 2026 financial results, reporting growth across all three business segments and increasing its full-year 2026 outlook.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
During its third-quarter 2026 earnings call, Bausch Health Companies Inc. addressed potential strategic options regarding its ownership stake in Bausch + Lomb Corporation.
Frederick Munsch, Senior Vice President, Controller, and Chief Accounting Officer of Bausch + Lomb, sold 112,015 common shares for approximately $2.29 million.
HC Wainwright & Co. has downgraded Bausch + Lomb Corporation from Buy to Neutral while increasing its price target to $22 from $21.
A recent survey of 14 analysts by FactSet has resulted in an upward revision of Bausch + Lomb Corporation's 2026 earnings per share (EPS) estimate and price target.
Multiple financial institutions, including RBC, Leerink Partners, and Jefferies, increased their price targets for Bausch + Lomb on October 29, 2026, following the company's third-quarter earnings report.